Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 9730 Download: 401 Web of Science: 19 Crossref: 25

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 6455 Download: 248 Web of Science: 7 Crossref: 13

Original Article

Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver disease by decreasing ubiquitin-mediated carnitine palmitoyl transferase 1A

Yuli Lin, Wulei Hou, Mengxiao Ge, Zhihao Wu, Linlin Huang, Haoye Liu, Wenli Zhang, Xiyu Deng, Lanxin Wang, Ming Guan, Chunhua Song, Zuoyun Wang, Dongqin Yang

Clin Mol Hepatol. 2025;31(4):1333-1354. Published online August 8, 2025

DOI: https://doi.org/10.3350/cmh.2024.1041

View: 3239 Download: 414

Review

Prospects of Mendelian randomization in hepatology: a comprehensive literature review with practice guidance

Lanlan Chen, Qi Rao, Menghan Gao, Guoyue Lv, Frank Tacke

Clin Mol Hepatol. 2025;31(4):1115-1138. Published online June 9, 2025

DOI: https://doi.org/10.3350/cmh.2025.0541

View: 2987 Download: 201 Crossref: 3

Letter to the Editor

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou

Clin Mol Hepatol. 2025;31(3):e252-e253. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0189

View: 6022 Download: 69

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(3):e239-e246. Published online January 21, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165

View: 6640 Download: 87

Snapshot

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease

Pingping Jin, Xinyi Lu, Daozhen Chen, Yu Chen

Clin Mol Hepatol. 2025;31(3):1100-1102. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1090

View: 6383 Download: 133 Web of Science: 1 Crossref: 1

Original Article

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study

Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(3):1084-1099. Published online April 23, 2025

DOI: https://doi.org/10.3350/cmh.2024.1096

View: 8564 Download: 254 Web of Science: 2 Crossref: 2

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States

Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(3):1058-1070. Published online April 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0169

View: 8238 Download: 140 Web of Science: 4 Crossref: 5

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease

Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim

Clin Mol Hepatol. 2025;31(3):1018-1031. Published online April 4, 2025

DOI: https://doi.org/10.3350/cmh.2024.1183

View: 8607 Download: 186 Web of Science: 1 Crossref: 2

Review

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment

Hee Yeon Kim, Mary E. Rinella

Clin Mol Hepatol. 2025;31(3):753-770. Published online April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0083

View: 8158 Download: 276 Web of Science: 3 Crossref: 4

Reply to Correspondence

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0070

View: 3970 Download: 30

Correspondence

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e210-e211. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1175

View: 4808 Download: 33

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171

View: 4764 Download: 35

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 4747 Download: 39

Letter to the Editor

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”

Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li

Clin Mol Hepatol. 2025;31(2):e145-e148. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0921

View: 5378 Download: 88

Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Hai Xu, Yong Zhou, Huikun Wu

Clin Mol Hepatol. 2025;31(2):e125-e127. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1087

View: 4870 Download: 38 Crossref: 1

Editorial

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 4835 Download: 48 Web of Science: 2 Crossref: 2

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”

Myeung Gi Choi, Na Young Lee, Ja Hyun Koo

Clin Mol Hepatol. 2025;31(2):592-595. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0971

View: 5296 Download: 113 Web of Science: 1 Crossref: 1

Correspondence

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Baokai Sun, Likun Zhuang

Clin Mol Hepatol. 2025;31(1):e67-e69. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0744

View: 3421 Download: 87

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878

View: 4255 Download: 36

Letter to the Editor

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719

View: 4278 Download: 83 Web of Science: 1 Crossref: 1

Editorial

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Andrea Caddeo, Rosellina M. Mancina

Clin Mol Hepatol. 2025;31(1):293-296. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0703

View: 4452 Download: 118 Crossref: 3

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Won Sohn

Clin Mol Hepatol. 2025;31(1):277-280. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0823

View: 5196 Download: 52 Web of Science: 3 Crossref: 3

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Yangyue Zhang, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2025;31(1):264-267. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0766

View: 6899 Download: 65 Web of Science: 1 Crossref: 2

Original Article

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(1):227-239. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0564

View: 5220 Download: 169 Web of Science: 9 Crossref: 12

USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination

Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li

Clin Mol Hepatol. 2025;31(1):147-165. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0478

View: 7395 Download: 640 Web of Science: 10 Crossref: 9

Review

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782

View: 6126 Download: 219 Web of Science: 4 Crossref: 5

Roles of X-box binding protein 1 in liver pathogenesis

Jihoon Tak, Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2025;31(1):1-31. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0441

View: 7650 Download: 208 Web of Science: 2 Crossref: 2

Special Topic

A new Korean nomenclature for steatotic liver disease

Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2024;30(Suppl):S214-S216. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0467

View: 4542 Download: 100 Crossref: 3

1 | 2 |

Viewed By 19872	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 15731	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 11162	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 11129	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 9271	MAFLD: How is it different from NAFLD?

Cited By 434	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 420	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 278	MAFLD: How is it different from NAFLD?
Cited By 206	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Cited By 148	Non-alcoholic fatty liver disease: Definition and subtypes

Search